Tucker Asset Management’s scPharmaceuticals SCPH Stock Holding History

Tucker Asset Management’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-28	Closed	-$285	–	1527
2023 Q2	$285	Hold	28	–	–	﹤0.01%	1069
2023 Q1	$254	Buy	+28	New	+$205	﹤0.01%	1093

Other funds holding SCPH

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Tucker Asset Management's SCPH Position: Q3 2023 in Review

Tucker Asset Management sold out of scPharmaceuticals (SCPH) in Q3 2023, closing a stake of 28 shares — an estimated $285 sold.

Tucker Asset Management first reported a position in SCPH in Q1 2023 and held it in 2 quarters. The position peaked at $285 in Q2 2023. 73 funds tracked by Wall St. Rank hold SCPH as of Q3 2023.

Tucker Asset Management reported no remaining scPharmaceuticals position as of Q3 2023 after selling out during the quarter.
Tucker Asset Management sold 28 scPharmaceuticals shares in Q3 2023, an estimated $285.
Tucker Asset Management first reported a position in scPharmaceuticals in Q1 2023 and held it in 2 quarters.
Tucker Asset Management's scPharmaceuticals position peaked at $285 in Q2 2023.
73 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2023.

Based on Tucker Asset Management's 13F filing for Q3 2023, filed 4 Dec 2023.